Key Quantitative Figures

  • Newly operational module one provides 7000L total reactor capacity
  • Includes 750L of solid-phase peptide synthesis (SPPS)
  • Includes 6250L liquid-phase peptide synthesis (LPPS)
  • Supported by three DAC columns: one 45 cm and two 60 cm
  • Two lyophilisers with 100 L and 200 L capacities
  • Module one required a $30 million investment
  • Module two planned to provide overall reactor capacity of up to 18,000 L
  • Module two will comprise three 5,000 L LPPS reactors
  • Module two will include either a 1,000 L or 2,000 L SPPS reactor
  • Module two will include smaller reactors of up to 1,000 L scale
  • Module one is supported by a team of nearly 212 peptide experts
  • Company has filed over 1000 DMFs globally
  • Company offers more than 100 APIs across multiple therapeutic areas
  • Revenues rose by 116% in most recent quarterly results

Dates of Action

  • September 15, 2026: Date of regulatory intimation and press release
  • First commercial peptide manufacturing module now operational as of this date

Entities Involved

  • Neuland Laboratories Limited (the company)
  • BSE Limited
  • National Stock Exchange of India Ltd
  • Big pharma and biotech companies (customers)

Purpose and Rationale

The expansion is aimed at meeting rising customer demand for peptide manufacturing capacity. The company is accelerating its peptide manufacturing expansion to support a broad range of peptide programmes and production scales, particularly as peptide pipelines expand and biotech companies struggle to access capable outsourced development and commercial manufacturing capacity.

Operational Impact

The expansion enables flexible customer programmes from small-scale to multikilogram quantities for complete peptide APIs, including complex and long-chain peptides, as well as commercial scale production of crude peptides. The SPPS and LPPS reactors are housed in different suites enabling parallel operation.

Strategic Updates

The range of partner indications is broadening beyond obesity and metabolic disease, with oncology emerging as a particularly active area of early-stage development. The company is exploring options to meet future demand over the next decade as it deepens strategic partnerships with leading pharma and biotech companies.

Financial Performance Context

Revenues rose by 116% in the company's most recent quarterly results, driven chiefly by increased commercial contracts as well as a growing number of clinical projects.

Company Background

Neuland Laboratories Limited is a specialist API CDMO partner serving clients in over 80 countries. The company operates three US FDA and EU GMP-compliant facilities in India with a combined reactor capacity of approximately 1218kL. The company invested in a new commercial scale peptide facility in 2026 and is opening a large, dedicated R&D process development centre in Hyderabad.